We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Meets With Mixed Reviews on Early Drug Trials
FDA Meets With Mixed Reviews on Early Drug Trials
January 25, 2006
While praised by the pharmaceutical industry, the FDA’s latest plan to accelerate clinical trials to get more drugs in the pipeline is facing a backlash from some lawmakers and advocacy groups who point to the proposal as evidence the agency is too close to industry and does not place enough emphasis on public health.